Vir Biotechnology Reports Q3 Net Loss of $96.3 Million

Vir reported a Q3 2026 net loss of $96.3 million, or $0.57 per share, compared with $163.1 million, or $1.17 per share, in Q3 2025. It had approximately $901.3 million in cash, cash equivalents and investments, which it expects to fund operations into the second half of 2028.